These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis. Paschos P; Ioakim K; Malandris K; Koukoufiki A; Nayfeh T; Akriviadis E; Tsapas A; Bekiari E Anaerobe; 2021 Oct; 71():102441. PubMed ID: 34454094 [TBL] [Abstract][Full Text] [Related]
11. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients. Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028 [TBL] [Abstract][Full Text] [Related]
12. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Johnson TM; Molina KC; Howard AH; Schwarz K; Allen L; Huang M; Bajrovic V; Miller MA Clin Infect Dis; 2022 May; 74(9):1572-1578. PubMed ID: 34665248 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study. Meschiari M; Cozzi-Lepri A; Cervo A; Granata G; Rogati C; Franceschini E; Casolari S; Tatarelli P; Giacobbe DR; Bassetti M; Pinna SM; De Rosa FG; Barchiesi F; Canovari B; Lorusso C; Russo G; Cenderello G; Cascio A; Petrosillo N; Mussini C Int J Infect Dis; 2023 Jun; 131():147-154. PubMed ID: 37030653 [TBL] [Abstract][Full Text] [Related]
14. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686 [TBL] [Abstract][Full Text] [Related]
15. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Alhifany AA; Almutairi AR; Almangour TA; Shahbar AN; Abraham I; Alessa M; Alnezary FS; Cheema E BMJ Open; 2019 Nov; 9(11):e031145. PubMed ID: 31699731 [TBL] [Abstract][Full Text] [Related]
16. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389 [TBL] [Abstract][Full Text] [Related]
17. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621 [TBL] [Abstract][Full Text] [Related]
18. Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience. Olmedo M; Kestler M; Valerio M; Padilla B; Rodríguez González C; Chamarro E; Machado M; Álvarez-Uría A; Alcalá L; Muñoz P; Bouza E Rev Esp Quimioter; 2022 Jun; 35(3):279-283. PubMed ID: 35279984 [TBL] [Abstract][Full Text] [Related]
19. AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge. Guilleman MM; Stevens BAY; Van Lieshout LP; Rghei AD; Pei Y; Santry LA; Thompson B; Wootton SK Gene Ther; 2023 May; 30(5):455-462. PubMed ID: 33608675 [TBL] [Abstract][Full Text] [Related]
20. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence? Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]